ORDER: 999999-9999
PATIENT: Sample Patient
ID: 999999
SEX: Female
AGE: 39
DOB: 00/00/1985

CLIENT #: 999999
DOCTOR: Sample Doctor MD
Doctors Data Inc
123 Main St.
St. Charles, IL 60174 USA

Comprehensive Stool Analysis

BACTERIOLOGY CULTURE

Expected/Beneficial Bacteria	Commensal (Imbalanced) flora	Dysbiotic flora
4+ *Bacteroides* family	1+ *Kocuria rhizophila*	4+ *Pseudomonas aeruginosa*
3+ *Bifidobacterium* family	3+ *Streptococcus anginosus*	
4+ *Escherichia coli*		
3+ *Lactobacillus* family		
4+ *Enterococcus* family		
2+ *Clostridium* family		

MALDI-TOF

NG = No Growth

BACTERIA INFORMATION

Expected / Beneficial bacteria make up a significant portion of the total microflora in a healthy & balanced GI tract. These beneficial bacteria have many health-protecting effects in the GI tract including manufacturing vitamins, fermenting fibers, digesting proteins and carbohydrates, and propagating anti-tumor and anti-inflammatory factors.

Clostridia are prevalent flora in a healthy intestine. Clostridium spp. should be considered in the context of balance with other expected/beneficial flora. Absence of clostridia or over abundance relative to other expected/beneficial flora indicates bacterial imbalance. If Clostridioides difficile associated disease is expected, a GI Pathogens PCR test is recommended.

Commensal (Imbalanced) bacteria are usually neither pathogenic nor beneficial to the host GI tract. Imbalances can occur when there are insufficient levels of beneficial bacteria and increased levels of commensal bacteria. Certain commensal bacteria are reported as dysbiotic at higher levels.

Dysbiotic bacteria consist of known pathogenic bacteria and those that have the potential to cause disease in the GI tract. They can be present due to a number of factors including: consumption of contaminated water or food, exposure to chemicals that are toxic to beneficial bacteria; the use of antibiotics, oral contraceptives or other medications; poor fiber intake and high stress levels. Aeromonas, Plesiomonas, Salmonella, Shigella, Vibrio, Yersinia, & Edwardsiella tarda have been specifically tested for and found absent unless reported.

YEAST CULTURE

Normal flora	Dysbiotic flora
1+ *Rhodotorula mucilaginosa*	

MALDI-TOF

YEAST INFORMATION

Yeast may normally be present in small quantities in the skin, mouth, and GI tract as a component of the resident microbiota. Their presence is generally benign. Recent studies, however, show that high levels of yeast colonization is associated with several inflammatory diseases of the GI tract. Animal models suggest that yeast colonization delays healing of inflammatory lesions and that inflammation promotes colonization. These effects may create a cycle in which low-level inflammation promotes fungal colonization and this colonization promotes further inflammation. Consideration of clinical intervention for yeast should be made in the context of other findings and presentation of symptoms.

SPECIMEN DATA

Comments:

Date Collected: 09/22/2025
Date Received: 09/25/2025
Date Reported: 10/02/2025
Methodology: Culture and identification by MALDI-TOF and conventional biochemicals

ORDER: 999999-9999
PATIENT: Sample Patient
ID: 999999
SEX: Female
AGE: 39
DOB: 00/00/1985

CLIENT #: 999999
DOCTOR: Sample Doctor MD
Doctors Data Inc
123 Main St.
St. Charles, IL 60174 USA

GI Pathogens; Multiplex PCR; stool

Viruses	Result	Reference Interval
Adenovirus F40/41	Negative	Negative
Norovirus GI/GII	Negative	Negative
Rotavirus A	Negative	Negative

Pathogenic Bacteria	Result	Reference Interval
Campylobacter (*C. jejuni*, *C. coli* and *C. lari*)	Negative	Negative
Clostridioides difficile (Toxin A/B)	Negative	Negative
Escherichia coli O157	Negative	Negative
Enterotoxigenic *Escherichia coli* (ETEC) lt/st	Negative	Negative
Salmonella spp.	Negative	Negative
Shiga-like toxin-producing *Escherichia coli* (STEC) stx1/stx2	Negative	Negative
Shigella (*S. boydii*, *S. sonnei*, *S. flexneri* & *S. dysenteriae*)	Negative	Negative
Vibrio cholerae	Negative	Negative

SPECIMEN DATA

Comments:

Date Collected: 09/22/2025
Date Received: 09/25/2025
Date Reported: 10/02/2025
Methodology: Multiplex PCR

ORDER: 999999-9999
PATIENT: Sample Patient
ID: 999999
SEX: Female
AGE: 39
DOB: 00/00/1985

CLIENT #: 999999
DOCTOR: Sample Doctor MD
Doctors Data Inc
123 Main St.
St. Charles, IL 60174 USA

Stool Chemistries

Digestion / Absorption	Result	Unit	Reference Interval
Elastase	>500	µg/g	> 200
Fat Stain	Not Detected		None – Moderate
Carbohydrates†	Negative		Negative

Inflammation	Result	Unit	Reference Interval
Lactoferrin	1.8	µg/mL	< 7.3
Calprotectin	<10	µg/g	< 80
Lysozyme*	540	ng/mL	≤ 500

Immunology	Result	Unit	Reference Interval
Secretory IgA*	4.4	mg/dL	30 – 275

Short Chain Fatty Acids	Result	Unit	Reference Interval
% Acetate‡	63	%	50 – 72
% Propionate‡	15	%	11 – 25
% Butyrate‡	20	%	11 – 32
% Valerate‡	1.7	%	0.8 – 5.0
Butyrate‡	2.5	mg/mL	0.8 – 4.0
Total SCFA's‡	12	mg/mL	5.0 – 16.0

Intestinal Health Markers	Result	Unit	Reference Interval
pH	6.5		5.8 – 7.0
Occult Blood	Negative		Negative

Macroscopic Appearance	Result	Unit	Reference Interval
Color	Brown		Brown
Consistency	Soft		Soft

Chemistry Information

Elastase findings can be used for assessing pancreatic exocrine function and insufficiency.

Fat Stain: Microscopic determination of fecal fat using Sudan IV staining is a qualitative procedure utilized to assess fat absorption and to detect steatorrhea.

SPECIMEN DATA

Comments:
Date Collected: 09/22/2025
Date Received: 09/25/2025
Date Reported: 10/02/2025
Methodology: Turbidimetric immunoassay, Microscopy, Colormetric, Elisa, Gas Chromotography, Guaiac, Macroscopic Observation

RI= Reference Interval, Toggles: Green = within RI, Yellow = moderately outside RI, Red = outside RI

*This test was developed and its performance characteristics determined by Doctor's Data Laboratories in a manner consistent with CLIA requirements. The U. S. Food and Drug Administration (FDA) has not approved or cleared this test; however, FDA clearance is not currently required for clinical use. The results are not intended to be used as a sole means for clinical diagnosis or patient management decisions.

†This test has been modified from the manufacturer's instructions and its performance characteristics determined by Doctor's Data Laboratories in a manner consistent with CLIA requirements.

‡This test was developed and its performance characteristics determined by Doctor's Data Laboratories in a manner consistent with CLIA requirements. The U.S. Food and Drug Administration (FDA) has not approved or cleared this test; however, FDA clearance is not currently required for clinical use.

Carbohydrates: The presence of reducing substances in stool specimens can indicate carbohydrate malabsorption.

Lactoferrin and **Calprotectin** are reliable markers for differentiating organic inflammation (IBD) from function symptoms (IBS) and for management of IBD. Monitoring levels of fecal lactoferrin and calprotectin can play an essential role in determining the effectiveness of therapy, are good predictors of IBD remission, and can indicate a low risk of relapse.

Lysozyme is an enzyme secreted at the site of inflammation in the GI tract and elevated levels have been identified in IBD patients.

Secretory IgA (sIgA) is secreted by mucosal tissue and represents the first line of defense of the GI mucosa and is central to the normal function of the GI tract as an immune barrier. Elevated levels of sIgA have been associated with an upregulated immune response.

Short chain fatty acids (SCFAs): SCFAs are the end product of the bacterial fermentation process of dietary fiber by beneficial flora in the gut and play an important role in the health of the GI as well as protecting against intestinal dysbiosis. Lactobacilli and bifidobacteria produce large amounts of short chain fatty acids, which decrease the pH of the intestines and therefore make the environment unsuitable for pathogens, including bacteria and yeast. Studies have shown that SCFAs have numerous implications in maintaining gut physiology. SCFAs decrease inflammation, stimulate healing, and contribute to normal cell metabolism and differentiation. Levels of **Butyrate** and **Total SCFA** in mg/mL are important for assessing overall SCFA production, and are reflective of beneficial flora levels and/or adequate fiber intake.

Color: Stool is normally brown because of pigments formed by bacteria acting on bile introduced into the digestive system from the liver. While certain conditions can cause changes in stool color, many changes are harmless and are caused by pigments in foods or dietary supplements.

Consistency: Stool normally contains about 75% water and ideally should be formed and soft. Stool consistency can vary based upon transit time and water absorption.

SPECIMEN DATA

Comments:

Date Collected: 09/22/2025
Date Received: 09/25/2025
Date Reported: 10/02/2025
Methodology:

ORDER: 999999-9999
PATIENT: Sample Patient
ID: 999999
SEX: Female
AGE: 39
DOB: 00/00/1985

CLIENT #: 999999
DOCTOR: Sample Doctor MD
Doctors Data Inc
123 Main St.
St. Charles, IL 60174 USA

Bacterial Susceptibilities

Pseudomonas aeruginosa

NATURAL ANTIBACTERIALS



PRESCRIPTIVE AGENTS



Natural antibacterial agents may be useful for treatment of patients when organisms display in-vitro sensitivity to these agents. The test is performed by using standardized techniques and filter paper disks impregnated with the listed agent. Relative sensitivity is reported for each natural agent based upon the diameter of the zone of inhibition surrounding the disk. Data based on over 5000 individual observations were used to relate the zone size to the activity level of the agent. A scale of relative sensitivity is defined for the natural agents tested.

Susceptible results imply that an infection due to the bacteria may be appropriately treated when the recommended dosage of the tested antimicrobial agent is used. **Intermediate** results imply that response rates may be lower than for susceptible bacteria when the tested antimicrobial agent is used. **Resistant** results imply that the bacteria will not be inhibited by normal dosage levels of the tested antimicrobial agent.

SPECIMEN DATA

Comments:

Date Collected: 09/22/2025
Date Received: 09/25/2025
Date Reported: 10/02/2025
Methodology: Disk Diffusion

*This test was developed and its performance characteristics determined by Doctor's Data Laboratories in a manner consistent with CLIA requirements. The U. S. Food and Drug Administration (FDA) has not approved or cleared this test; however, FDA clearance is not currently required for clinical use. The results are not intended to be used as a sole means for clinical diagnosis or patient management decisions.

Introduction

This analysis of the stool specimen provides fundamental information about the overall gastrointestinal health of the patient. When abnormal microflora or significant aberrations in intestinal health markers are detected, specific commentaries are presented. If no significant abnormalities are found, commentaries are not presented.

The majority of reference intervals are established from adult populations. Results may differ in pediatric populations and care should be taken when interpreting these values.

Microbiology

Imbalanced Flora

Imbalanced flora are those bacteria that reside in the host gastrointestinal tract and neither injure nor benefit the host. Certain dysbiotic bacteria may appear under the imbalanced category if found at low levels because they are not likely pathogenic at the levels detected. Imbalanced bacteria are commonly more abundant in association with insufficiency dysbiosis, and/or a fecal pH more towards the alkaline end of the reference range (5.8 - 7.0). Treatment with antimicrobial agents is unnecessary unless bacteria appear under the dysbiotic category.

Pathogenic/Dysbiotic Flora

In a healthy balanced state of intestinal flora, the beneficial bacteria make up a significant proportion of the total microflora. However, in many individuals there is an imbalance or deficiency of beneficial flora (insufficiency dysbiosis) and an overgrowth of non-beneficial (imbalance) or even pathogenic microorganisms. This can be due to a number of factors including: consumption of contaminated water or food; daily exposure of chemicals that are toxic to beneficial bacteria; the use of antibiotics, oral contraceptives or other medications; poor fiber intake and high stress levels.

A number of toxic substances can be produced by the dysbiotic bacteria including amines, ammonia, hydrogen sulfide, phenols, and secondary bile acids which may cause inflammation or damage to the brush border of the intestinal lining. If left unchecked, long-term damage to the intestinal lining may result in leaky gut syndrome, allergies, autoimmune disease (e.g. rheumatoid arthritis), irritable bowel syndrome, fatigue, chronic headaches, and sensitivities to a variety of foods. In addition, pathogenic bacteria can cause acute symptoms such as abdominal pain, nausea, diarrhea, vomiting, and fever in cases of food poisoning.

Bacterial sensitivities to a variety of prescriptive and natural agents have been provided for the pathogenic bacteria that were cultured from this patient's specimen. This provides the practitioner with useful information to help plan an appropriate treatment regimen. Supplementation with probiotics or consumption of foods (yogurt, kefir, miso, tempeh, tamari sauce) containing strains of lactobacilli, bifidobacteria, and enterococci may help restore healthy flora levels. Soluble fiber and polyphenols derived from chocolate, green tea, blackcurrant, red wine and grape seed extracts have been found to increase the numbers of beneficial bacteria. Hypochlorhydria may also predispose an individual to bacterial overgrowth, particularly in the small intestine. Nutritional anti-inflammatories can aid in reversing irritation to the GI lining. These include quercetin, vitamin C, curcumin, gamma-linoleic acid, omega-3 fatty acids (EPA, DHA), and aloe vera. Other nutrients such as zinc, beta-carotene, pantothenic acid, and L-glutamine provide support for regeneration of the GI mucosa. A comprehensive program may be helpful in individuals in whom a dysbiotic condition has caused extensive GI damage.

Pseudomonas aeruginosa

Pseudomonas aeruginosa is a gram-negative aerobic bacillus belonging to the bacterial family *Pseudomonadaceae*. This opportunistic pathogen is considered dysbiotic in the amount of 3+ - 4+. *P. aeruginosa* is tolerant to a wide variety of physical conditions and temperatures. The exact source and mode of transmission is not known due to its ubiquitous presence in the environment. This bacterium has minimal nutritional requirements and is very resistant to disinfectants and most antibiotics. It survives in moist environments and can therefore grow in bottled non-carbonated mineral water, distilled water, tap water, and food. *Pseudomonas* can cause urinary tract infections, dermatitis, soft tissue infections, bacteremia, endocarditis, and osteochondritis. Skin and soft tissue infections can also proliferate in high moisture conditions (swimmer's ear, toe webs of athletes, skin of hot tub users).

Gastrointestinal colonization of immunocompromised patients with *P. aeruginosa* may lead to bacteremia. Gastrointestinal infections are found primarily in these immunosuppressed patients; however, a number of cases of diarrhea have been reported in otherwise healthy individuals. *Pseudomonas* is often asymptomatic in the gastrointestinal tract, but is considered a potential cause of antibiotic associated diarrhea.

For the otherwise healthy individual, antimicrobial therapy is often unnecessary. Antibiotics may be indicated if symptoms are prolonged and in systemic infections. Refer to the antimicrobial sensitivities to identify appropriate therapy.

Cultured Yeast

Small amounts of yeast (+1) may be present in a healthy GI tract. However higher levels of yeast (> +1) are considered to be dysbiotic. A positive yeast culture and sensitivity to prescriptive and natural agents may help guide decisions regarding potential therapeutic intervention for yeast overgrowth. When investigating the presence of yeast, disparity may exist between culturing and microscopic examination. Yeast grows in colonies and is typically not uniformly dispersed throughout the stool. Further, some yeast may not survive transit through the intestines rendering it unviable for culturing. This may lead to undetectable or low levels of yeast identified by culture, despite a significant amount of yeast visualized microscopically. Therefore, both microscopic examination and culture are helpful in determining if abnormally high levels of yeast are present.

GI Pathogens

Introduction

The GI Pathogen profile is performed using an FDA-cleared multiplex PCR system. It should be noted that PCR testing is much more sensitive than traditional techniques and allows for the detection of extremely low numbers of pathogens. PCR testing does not differentiate between viable and non-viable pathogens and should not be repeated until 21 days after completion of treatment or resolution to prevent false positives due to lingering traces of DNA. PCR testing can detect multiple pathogens in the patient's stool but does not differentiate the causative pathogen. All decisions regarding the need for treatment should take the patient's complete clinical history and presentation into account.

Stool Chemistries

Lysozyme

The level of lysozyme is elevated in this sample. Lysozyme is a biomarker of an inflammatory immune response in the gut. Moderate elevations in lysozyme are commonly associated with significant overgrowth of enteropathogens such as yeast, dysbiotic or pathogenic bacteria. Markedly elevated levels of lysozyme may occur with inflammatory bowel disease (IBD), such as Crohn's disease and Ulcerative colitis as well as other non-IBD intestinal diseases with diarrhea. If lysozyme is markedly elevated check the levels of calprotectin and lactoferrin. If either or both are very elevated reassess the levels in about four weeks. Lysozyme is commonly elevated for actively breast-feeding infants due to high maternal milk content.

Lysozyme is helpful in the determination of pathogen-induced inflammatory activity rather than IBD. Slightly-to moderately elevated levels of lysozyme may be remediated with elimination of an offending enteroinvasive microorganism and use of anti-inflammatory nutraceuticals.

Secretory IgA (sIgA) Low

The concentration of sIgA is abnormally low in this fecal specimen. Secretory IgA represents the first line of defense of the gastrointestinal (GI) mucosa and is central to the normal function of the GI tract as an immune barrier. Immunological activity in the gastrointestinal tract can be accessed via fecal sIgA levels in a formed stool sample. However, sIgA may be artefactually low due to fluid dilution effects in a watery or loose/watery stool sample.

Chronic mental and physical stress as well as inadequate nutrition have been associated with low fecal sIgA concentrations. This includes dietary restrictions, excessive alcohol intake, body mass loss, negative moods, and anxiety. One study found decreased levels of sIgA in malnourished children, particularly protein malnourishment, which responded well to nutritional rehabilitation with a significant increase in sIgA. A possible explanation for this may be the synthesis and expression of sIgA requires adequate intake of the amino acid L-glutamine. An increase of dietary L-glutamine may restore GI immune function by protection of cells that synthesize sIgA. *Saccharomyces boulardii* is a nonpathogenic yeast that has been used for the treatment of acute infectious enteritis and antibiotic-associated diarrhea. Restored levels of sIgA and subsequent enhanced host immune response have been found following *S. boulardii* administration (animal models). With low sIgA one might consider a salivary cortisol test.